COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT  REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products base ...